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ABSTRACT
CONTEXT AND OBJECTIVE: Among burn patients, it is common to use colloidal substances under the justification that it is necessary to correct the 
oncotic pressure of the plasma, thereby reducing the edema in the burnt area and the hypotension. The aim here was to assess the risk of hospital 
mortality, comparing the use of albumin and crystalloid solutions for these patients. 
DESIGN AND SETTING: Non-concurrent historical cohort study at Faculdade de Medicina de Marília; within the Postgraduate program on Internal and 
Therapeutic Medicine, Universidade Federal de São Paulo; and at the Brazilian Cochrane Center. 
METHODS: Burn patients hospitalized between 2000 and 2001, with registration in the Hospital Information System, who received albumin, were 
compared with those who received other types of volume replacement. The primary outcome was the hospital mortality rate. The data were collected 
from files within the Datasus software. 
RESULTS: 39,684 patients were included: 24,116 patients with moderate burns and 15,566 patients with major burns. Among the men treated with 
albumin, the odds ratio for the risk of death was 20.58 (95% confidence interval, CI: 11.28-37.54) for moderate burns and 6.24 (CI 5.22-7.45) for 
major burns. Among the women, this risk was 40.97 for moderate burns (CI 21.71-77.30) and 7.35 for major burns (CI 5.99-9.01). The strength of 
the association between the use of albumin and the risk of death was maintained for the other characteristics studied, with statistical significance.  
CONCLUSION: The use of albumin among patients with moderate and major burns was associated with considerably increased mortality.
RESUMO 
CONTEXTO E OBJETIVO: Em pacientes queimados é comum o uso de substâncias coloidais sob justificativa de que é necessário corrigir a pressão 
oncótica do plasma, reduzindo o edema na área queimada e a hipotensão. O objetivo foi avaliar o risco de mortalidade hospitalar, comparando o 
uso de albumina e soluções cristaloides para esses pacientes. 
TIPO DE ESTUDO E LOCAL: Estudo coorte histórico não concorrente na Faculdade de Medicina de Marília, no Programa de Pós-Graduação em 
Medicina Interna e Terapêutica da Universidade Federal de São Paulo e no Centro Cochrane do Brasil.
MÉTODOS: Pacientes queimados hospitalizados entre 2000 e 2001, registrados no Sistema de Informações Hospitalares e que receberam albumina 
foram comparados com aqueles que receberam outros tipos de reposição volêmica. O desfecho primário foi a taxa de mortalidade hospitalar. Os 
dados foram coletados dos arquivos do programa Datasus. 
RESULTADOS: Foram incluídos 39.684 pacientes: sendo 24.116 pacientes com queimaduras moderadas e 15.566 pacientes com queimaduras 
graves. Entre os homens tratados com albumina, o odds ratio para o risco de morte foi 20,58 (intervalo de confiança IC 95% 11,28-37,54) para 
queimaduras moderadas e 6,24 (IC 5,22-7,45) para queimaduras graves. Entre as mulheres, esse risco foi de 40,97 para queimaduras moderadas 
(IC 21,71-77,30) e 7,35 para queimaduras graves (IC 5,99-9,01). A força da associação entre o uso de albumina e o risco de morte foi mantida 
para as outras características estudadas, com significância estatística. 
CONCLUSÃO: O uso de albumina entre pacientes com queimaduras moderadas e graves foi associado a aumento considerável da mortalidade.
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INTRODUCTION
Burns are defined as injuries to organic tissue resulting from trau-
ma of thermal origin. The main consequences from such injuries are 
hemodynamic instability, shock, pain, hemorrhage, anemia, immu-
nodepression and functional sequelae.1,2 The worldwide mortality rate 
due to severe burns is around 8% and the patients that die are mostly 
those presenting second and third-degree burns that affect more than 
25% and 10% of the body surface, respectively, or when the burns af-
fect the face or perineum, or cause severe respiratory injuries.1,2
The recommended treatment for these patients takes into account 
the principal intercurrences that are possible during hospitalization. 
Analgesia and fluid replacement using isotonic and hypertonic solu-
tions have long been recommended and accepted.2-4
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However, it is very common practice to use colloidal substances, 
and among these, albumin, under the justification that it is necessary to 
correct the oncotic pressure of the plasma, thereby reducing the edema 
in the burnt area and the possible hypotension. 
The use of colloidal substances has been seriously questioned with 
regard to their efficiency, efficacy, effectiveness and safety. Recent sys-
tematic reviews and editorials have shown that the use of colloidal sub-
stances may cause increased hospital mortality among burn patients.5-7
In Brazil in the years 2000 and 2001, the National Health System 
(Sistema Único de Saúde, SUS) funded a mean of 12,300,000 hospital-
izations per year, at a mean annual cost of five billion reais. The number 
of deaths was around 300,000, with a mortality rate of 2.7% (Tables 1 
and 2). Burn patients were included among the surgical-clinical proce-
dures and represented 0.91% of the total number of hospitalizations for 
this specialty, over these two years. 
The ordinances of the Ministry of Health relating to severity of burn 
cases give the following definitions: 
a) Minor burn: Patients are considered to present minor burns if they 
have first and second-degree burns affecting up to 10% of their 
body area.
b) Moderate burns: Patients are considered to present moderate burns 
if they have:
 First and second-degree burns affecting between 10% and 25% 
of their body area, or
 Third-degree burns affecting up to 10% of their body area, or 
 Burns affecting their hands and feet. 
c) Major burns: Patients are considered to present major burns if they 
have:
 First and second-degree burns affecting 26% or more of their 
body area, or
 Third-degree burns affecting more than 10% of their body area, or 
 Burns affecting the perineum.3,4
Patients are classified as presenting major burns if they were the vic-
tims of burns of any extent that were associated with one or more of 
the following situations: inhalatory injuries, polytrauma, cranial trau-
ma, electrical trauma, shock, kidney failure, heart failure, liver failure, 
hemostasis disorders, pulmonary embolism, acute myocardial infarct, 
severe infectious conditions whether resulting from the burns or not, 
compartment syndrome and consumptive diseases.3,4
OBJECTIVE
The aim of this study was to assess the risk of hospital mortality, 
comparing treatments using albumin and crystalloid solutions for pa-
tients with moderate and major burns.
METHODS
This was a non-concurrent historical cohort study conducted at the 
Brazilian Cochrane Center, Universidade Federal de São Paulo (Unifesp) 
and Faculdade de Medicina de Marília (Famema). 
This study included patients with moderate and major burns who 
were hospitalized at reference centers in 2000 and 2001 and who ap-
peared in the records of the Hospital Information System of the De-
partment of Information Technology, Ministry of Health (Datasus). Pa-
tients classified as presenting minor burns, or those for whom it was not 
possible to specify whether the registered procedure related to moderate 
or major burns, were excluded. 
This was a convenience sample consisting of the total number of 
hospitalizations due to burns (49,343 cases in 2000 and 2001) that ap-
pear in the Hospital Information System, minus exclusions due to lack 
of definition of the procedures implemented and minus the cases of hos-
pitalization due to minor burns.
The database used to collect the data was the Hospital Informa-
tion System, which is stored in the Ministry of Health’s Datasus sys-
tem. All the information in the database was grouped in relation to 
Authorizations for Hospitalization, i.e. as information relating to indi-
viduals. Authorizations for Hospitalization not only have a billing role 
within the national public SUS but also, above all, are a powerful in-
strument for epidemiological information. They contain data such as 
gender, date of birth, profession, type of hospitalization, International 
Classification of Diseases (ICD) coding, procedures undertaken, spe-
cial procedures, number of days of hospitalization, reason for discharge 
or transfer, death, use of orthoses/prostheses, hemotherapy and atten-
dance location.
The use of albumin is classified as a special procedure, and therefore 
it is possible to identify, on a case-by-case basis, the quantity used and 
the amount spent on the treatment. When albumin is not used, it is as-
sumed that the patient received crystalloid solutions. 
Statistical analysis was performed on the 39,684 burn cases (moder-
ate and major burns) that were hospitalized through SUS in 2000 and 
2001. The patients’ identities were kept confidential, in accordance with 
legal determinations.
The outcome measured was the death rate, during hospitalization, 
among patients with moderate and major burns, who were registered 
through SUS in 2000 and 2001.
The information groupings and analysis were performed by means 
of the Tab Win software. The chi-square test was used for analyzing as-
sociations between the variables and odds ratios (ORs) were calculated 
for occurrences of death among cohorts corresponding to patients who 
received albumin and patients who did not receive albumin, for group-
ings defined by the variables of sex, burn category, age group and mean 
length of hospital stay. To analyze combined associations between vari-
ables, binary logistic regression analysis was used, taking P < 0.05 to in-
dicate significance for such associations. For ORs, 95% confidence in-
tervals were constructed, and these were used in assessing the statistical 
significance of the results.
RESULTS
The study included 39,684 patients. The sample represented all the 
patients hospitalized and registered through SUS in 2000 and 2001 
with moderate and major burns. 
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Table 1. Patient distribution according to the burn category, gender, age group, use of albumin and occurrence of deaths (Brazil 2000-2001)
Variables
Death in moderate burns
P
Death in major burns
PYes No Yes No
n % n % n % n %
Gender
Male 77 60.63 13,946 58.13
0.569
739 54.82 8,800 61.99
< 0.001Female 50 39.37 10,045 41.87 609 45.18 5,418 38.01
Total 127 100.00 23,991 100.00 1,348 100.00 14,218 100.00
Age group
≤ 19 years 20 15.75 14,925 62.28
< 0.001
323 54.91 7,801 54.91
< 0.001
20 to 39 23 18.11 5,085 21.22 415 26.71 3,795 26.71
40 to 59 33 25.98 2,841 11.86 346 13.61 1,933 13.61
≥ 60 51 40.16 1,115 4.64 264 4.78 679 4.78
Total 127 100.00 23,966* 100.00 1,348 100.00 14,208† 100.00
Mean length of hospital stay
≤ 7 days 73 57.48 17,290 72.1
< 0.001
944 70.03 5,557 39.08
0.009
8 to 14 26 20.47 4,687 19.5 234 17.36 5,190 36.50
15 to 21 16 12.60 1,145 4.8 76 5.64 1,700 11.96
≥ 22 12 9.45 869 3.6 94 6.97 1,771 12.46
Total 127 100.00 23,991 100.00 1,348 100.00 14,218 100.00
State where patient lived
São Paulo 21 16.54 2,807 11.70
< 0.001
247 18.32 2,215 15.58
< 0.001
Rio de Janeiro 17 13.39 1,019 4.25 138 10.24 713 5.01
Minas Gerais 18 14.17 3,275 13.65 188 13.95 1,457 10.25
Others 71 55.91 16,890 70.45 775 57.49 9,833 69.16
Total 127 100.00 23,991 100.00 1,348 100.00 14,218 100.00
Albumin
Used 29 22.83 253 1.05
< 0.001
419 31.08 901 6.34
< 0.001Not used 98 77.17 23,738 98.95 929 68.92 13,317 93.66
Total 127 100.00 23,991 100.00 1,348 100.00 14,218 100.00
*27 patients with unknown age; †10 patients with unknown age. 
The group with moderate burns consisted of 24,118 patients 
(60.77%). Among these, 282 (1.17%) received albumin during hospi-
talization and 29 died, thus representing a mortality rate of 10.28%. The 
vast majority of the patients with moderate burns (23,836; 98.83%) did 
not receive albumin. The mortality rate among this group was 0.41%. 
The total number of deaths in this group was 127 patients, with a mor-
tality rate of 0.53%.
The group with major burns consisted of 15,566 patients (39.23%), 
of whom 1,320 received albumin. Among these, there were 419 deaths, 
representing a mortality rate of 31.74%. The other 14,245 patients did 
not receive albumin during their hospitalization, and the mortality rate 
among these patients was 6.51%. The total number of deaths among 
patients with major burns was 1348, representing a mortality rate of 
8.66%.
Results according to variables
Table 1 presents the distributions of patients with moderate and 
major burns in relation to gender, age group, length of hospital stay, 
federal state where the patient was hospitalized, use of albumin and the 
main outcome (death). Examination of the data showed that there was 
a statistically non-significant association between sex and death due to 
moderate burns (P = 0.569) and a statistically significant association be-
tween sex and death due to major burns (P < 0.0001). The percentages 
of deaths among males due to moderate and major burns were 60.63% 
and 54.82%, respectively, and thus were greater than the percentages for 
females. The percentages of deaths among patients with moderate burns 
were 0.55% for males and 0.50% for females. Among the patients with 
major burns, the percentages were 7.75% and 10.10%, respectively. It 
was observed that the mortality rate among patients with major burns 
was greater for males. Among the patients with moderate burns, the 
mortality rates were similar for females and males.
Comparison between the age groups and death due to moderate 
burns (P < 0.001) and between the age groups and death due to major 
burns (P < 0.001) showed that there was a statistically significant differ-
ence between the age distributions for deaths due to moderate and ma-
jor burns (P < 0.001). The older the age group was, the greater the risk 
of death was, both for the group with moderate burns and for the group 
with major burns. 
Other statistically significant associations were found between the 
mean length of stay in hospital and death due to moderate burns (P < 
0.001) and between the mean length of hospital stay and death due to 
major burns (P < 0.001). These showed that there was a statistically sig-
nificant difference in the distributions of mean length of hospital stay, 
in relation to deaths due to moderate and major burns (P < 0.001). This 
indicated that the mortality rate was greater when the mean length of 
hospital stay was shorter, i.e. ≤ 7 days versus 8 to 14 days.
In relation to the federal state where the patient lived and death 
due to moderate burns (P = 0.001), a statistically significant associa-
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tion was observed. There was also a statistically significant association 
between federal state and death due to major burns (P < 0.008). How-
ever, there was no statistically significant difference in the distribution 
of federal states where the patients lived, between the deaths among pa-
tients with moderate burns and the deaths among patients with major 
burns (P = 0.471). A high proportion of the deaths in the group of pa-
tients with moderate burns occurred among the patients living in the 
State of São Paulo. 
Another observation was that there was a statistically significant as-
sociation between the use of albumin and death among the patients 
with moderate and major burns (P < 0.001). This showed a statistically 
significant difference in the distribution of the use of albumin between 
the deaths due to moderate burns and the deaths due to major burns 
(P < 0.001). There was a high proportion of deaths among the patients 
with moderate burns who received albumin. 
Specific results
The data in Table 2 show that, for all the groups defined by gender, 
burn category and use of albumin, there was a greater risk of death in the 
group that received albumin than in the group that did not receive it. Spe-
cifically, among the male patients with moderate burns, the risk of death 
in the group that received albumin was around 20 times greater; among 
the male patients with major burns, this risk was around six times greater; 
among the female patients with moderate burns, this risk was around 40 
times greater; and among the female patients with major burns, this risk 
was around seven times greater. Analysis of the results found indicated 
that they were statistically significant, with P < 0.001, and showed that 
the use of albumin was associated with increased hospital mortality.
For all the groups defined by age group, burn category and use of al-
bumin, there was a greater risk of death in the group that received albu-
min than in the group that did not receive albumin. Among the patients 
with moderate burns who were less than 19 years old, the risk of death 
in the group that received albumin was around 13 times greater than in 
the group that did not receive albumin; among the patients with ma-
jor burns who were 19 years of age or under, this risk was around seven 
times greater; among the patients with moderate burns who were in the 
age groups from 20 to 39 years, 40 to 59 years and 60 years and over, 
these risks were 40, 29 and 12 times greater, respectively; and among the 
patients with major burns, the risks for these groups were six, six and 
four times greater, respectively (Table 3).
Table 2. Patient distribution and odds ratio estimates for the risk of death, according to burn category, use of albumin, deaths and sex. Brazil, 2000-2001 
(P < 0.001)
Moderate burns Major burns
Deaths Deaths
Males
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 14 149 163 8.59
20.58
(11.28 -.37.53) 225 577 802 28.05
6.24 (5.22 – 7.45)Not used 63 13,797 13,860 0.45 514 8,223 8,737 5.88
Total 77 13,946 14,023 0.55 739 8,800 9,539 7.75
Females
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 15 104 119 12.60
40.97 (21.71 – 77.30)
194 324 518 37.45
7.35 (5.99 – 9.01)Not used 35 9,941 9,976 0.35 415 5,094 5,509 7.53
Total 50 10,045 10,095 0.50 609 5,418 6,027 0.10
Total 127 23,991 24,118 0.53 1,348 14,218 15,566 8.66
*25 patients with unknown age; †1 patient with unknown age; ‡10 patients with unknown age       
OR = odds ratio; CI = confidence interval.
Moderate burns Major burns
Deaths Deaths
≤ 19  
years
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 2 109 111 1.80
13.59 (3.14 – 58.86)
95 427 522 18.20
7.20 (5.56 – 9.32)Not used 20 14,816 14,836 0.13 228 7,374 7,602 2.94
Total 22 14,925 14,947 0.15 323 7,801 8,124 3.90
20 – 39 
years
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 9 79 88 10.23
40.57 (17.06 – 96.49)
150 292 442 33.93
Not used 14 5,006 5,020 0.28 264 3,503 3,767 7.00
Total 23 5,085 5,108 0.48 414 3,795 4,209 9.84
40 – 59 
years
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 10 42 52 19.23
28.08 (12.99 – 64.65)
114 134 248 45.97
6.60 (4.96 – 8.77)Not used 23 2,799 2,822 0.82 232 1,709 1,941 11.42
Total 33 2,841 2,874 1.14 346 1,843 2,189 15.18
≥ 60  
years
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 8 22 30 26.67
12.15 (5.41 – 27.31)
60 48 108 55.56
3.87 (2.56 – 5.83)Not used 41 1,093 1,134 3.62 204 631 835 24.43
Total 49 1,115 1,164 4.21 264 679 943 28.00
Total 127 23,966* 24,903 0.53 1,347† 14,118‡ 15,555 8.66
Table 3. Patient distribution and odds ratio estimates for the risk of death, according to burn category, use of albumin, deaths and age ranges. Brazil, 
2000-2001 (P < 0.001)
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For all the groups defined by the mean length of hospital stay, burn 
category and use of albumin, there was a greater risk of death in the 
group that received albumin than in the group that did not receive al-
bumin. Among the patients with moderate burns who stayed in hospital 
for less than seven days, the risk of death in the group that received albu-
min was around 73 times greater; among the patients with major burns 
who stayed in hospital for less than seven days, this risk was around 12 
times greater; among the patients with moderate burns who stayed in 
hospital for 8 to 14 days, 15 to 21 days and more than 21 days, these 
risks were 30, 10 and 5 times greater, respectively; and among the pa-
tients with major burns, the risks for these groups were 16, 11 and 5 
times greater, respectively (Table 4). 
The data in Table 5 also show that, for all the groups defined by the 
federal state where the patient lived, burn category and use of albumin, 
there was a greater risk of death in the group that received albumin than 
in the group that did not receive albumin. Specifically, among the patients 
with moderate burns who lived in the State of São Paulo, the risk of death 
in the group that received albumin was 51 times greater; among the pa-
tients with major burns who lived in the State of São Paulo, this risk was 
around seven times greater; among the patients with moderate burns who 
lived in the States of Rio de Janeiro, Minas Gerais and other states, these 
risks were 114, 13 and 30 times greater, respectively; and among the pa-
tients with major burns who lived in these locations, the risks for these 
groups were three, ten and six times greater, respectively.
Table 4. Patient distribution and odds ratio estimates for the risk of death, according to burn category, use of albumin, deaths and mean length of hospital 
stay. Brazil, 2000-2001 (P < 0.001)
Moderate burns Major burns
Deaths Deaths
≤ 7 days
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 11 39 50 22.00
78.48
(38.43 – 
160.28)
216 134 350 61.71
12.01 (9.55 – 15.10)Not used 62 17,251 17,313 0.36 728 5,423 6,151 11.84
Total 73 17,290 17,363 0.42 944 5,557 6,501 14.52
8 – 14 days
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 8 66 74 10.81
30.19 (12.69 – 71.81)
106 249 355 29.86
16.43 (12.33 – 21.90)Not used 18 4,619 4,637 0.39 128 4,941 5,069 2.53
Total 26 4,685 4,711 0.55 234 5,190 5,424 4.31
15 – 21 
days
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 6 64 70 8.57
10.13 (3.57 – 28.76)
44 193 237 18.57
10.74 (6.65 – 17.34)Not used 10 1,081 1,091 0.92 32 1,507 1,539 2.01
Total 16 1,145 1,161 1.38 76 1,700 1,776 4.27
≥ 22 days
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 4 82 86 4.65
4.80 (1.41 – 16.28)
53 48 101 52.47
5.7 (3.76 – 8.80)Not used 8 787 795 1.01 41 631 672 6.10
Total 12 869 881 1.36 94 679 773 12.16
Total 127 23,989 24,116 1.36 1,348 13,126 14,474 8.66
OR = odds ratio; CI = confidence interval.
Table 5. Patient distribution and odds ratio estimates for the risk of death, according to burn category, use of albumin, deaths and location (federal state). 
Brazil, 2000-2001 (P < 0.001)
Moderate burns Major burns
Deaths Deaths
São Paulo
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 11 63 74 14.66
47.91 (19.63 – 116.91)
114 249 363 31.40
6.77 (5.10 – 8.98)Not used 10 2,744 2,754 0.33 133 1,966 2,099 6.34
Total 21 2,807 2,828 0.71 247 2,215 2,462 10.03
Rio de 
Janeiro
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 6 68 74 8.11
7.63 (2.74 – 21.25)
58 147 205 28.29
2.90 (1.08 – 4.25)Not used 11 951 962 1.14 79 567 646 12.23
Total 17 1,019 1,036 1.64 137 714 851 16.10
Minas 
Gerais
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 2 31 33 6.66
13.01 (2.87 – 59.00)
100 150 250 40.00
9.90 (7.10 – 13.81)Not used 16 3,226 3,242 0.52 88 1,307 1,395 6.31
Total 18 3,257 3,275 0.58 188 1,457 1,645 7.69
Others
Albumin Yes No Total % OR 95% CI Yes No Total % OR 95% CI
Used 10 91 101 9.90
30.60 (15.20 – 61.63)
146 356 502 41.01
6.23 (5.05 – 7.68)Not used 61 16,811 16,872 0.38 630 9,477 10,107 6.23
Total 71 16,902 16,973 0.42 776 9,833 10,609 7.69
Total 127 23,985 24,112 0.53 1,348 14,219 15,567 8.66
OR = odds ratio, CI = confidence interval.
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Analysis of combined associations by means of logistic regression
Logistic regression analysis established the values for the variables 
of age group, mean length of hospital stay and federal state where the 
patient was hospitalized. The aim was to study the risk of death among 
the patients who received albumin when the combined effect of the 
other variables was taken into consideration. It was shown that the risk 
of death (expressed by ORs) among the patients who received albumin 
was OR = 7.39 (95% CI: 6.44 to 8.48) for the established variable of 
age group; OR = 12.06 (95% CI: 10.37 to 14.04) for the established 
variable of mean length of hospital stay; and OR = 8.56 (95% CI: 7.51 
to 9.76) for the established variable of federal state where the patient 
was hospitalized. Although the P-value in the Hosmer and Lemeshow 
test was less than 0.05 and the Nagelkerke R-square was greater than 
0.10, the P-value of the test model (which was less than 0.05) and 
the AUROC (area under the receiver operating characteristic curve) of 
0.12 indicated that the model had satisfactory discriminatory power. 
DISCUSSION
The analyses on the results from this study showed that there was a 
very high association between the use of human albumin and hospital 
mortality, for any presentation of patients with burns and in relation to 
the different variables analyzed (sex, age, location of hospitalization and 
length of hospital stay). The mortality rate increased with the use of al-
bumin among patients with moderate and major burns. 
Among the patients with moderate burns (less severe), for all the 
characteristics studied, the use of albumin was a risk factor for increased 
hospital mortality. Among the female patients, the risk of death was 40 
times greater (95% CI: 21.71-77.30) in the group treated with albumin, 
in relation to the control group. Among the male patients, the risk was 
20 times greater (95% CI: 11.28-37.54). Although less intensely, this 
relationship was repeated for all the other characteristics studied, and 
the association was confirmed by the logistic regression method. 
Among the patients with major burns (more severe), the risk of 
death through the use of albumin was also significant. The risk of death 
was seven times greater (95% CI: 5.99-9.01) among the female patients 
and six times greater (95% CI: 5.22-7.45) among the male patients. 
Just like among the patients with moderate burns, this relationship was 
maintained with the other variables.
The explanation that the increased mortality rate may have been 
influenced by the severity and extent of the burns does not stand up to 
examination, because the risk of death was higher among the patients 
with moderate burns, i.e. among those less severely affected. Some 
strong points can be highlighted in this study, among which is the fact 
that the sample was large and representative, considering that it includ-
ed all the patients with moderate and major burns (39,684 patients) 
who were hospitalized and registered through SUS in the years 2000 
and 2001. The exploratory analysis was extensive and the strength and 
consistency of the association were confirmed by the statistical tests. 
The independence of the analysis was sustained by information appear-
ing in the Ministry of Health’s Datasus database, i.e. the information is 
in the public domain and can be accessed for any type of rechecking. 
The results from the present study confirm the evidence brought to 
light in the various studies carried out by the Cochrane Injuries Group 
Albumin Review (systematic review with meta-analysis).6,7 Retrospec-
tive studies may contain failings relating to the trustworthiness of the 
information. In the case of the present study, such failings have been 
overcome, because there are some studies that compare the information 
appearing in the SUS Hospital Information System (authorizations for 
hospitalization) with the medical records, with the aim of analyzing the 
pertinence of the Datasus information and validating it.8,9 Following an 
analysis of 1036 authorization forms for hospitalization registered with 
a main diagnosis of acute myocardial infarct in the municipality of Rio 
de Janeiro in 1997, the results obtained demonstrated that the quality 
of the diagnosis was satisfactory, with a high percentage confirmation of 
91.7% (95% CI: 78.3-94.2). 
Some studies have tried to show the opposite, i.e. concluding in fa-
vor of using albumin, given that no harm was shown through its use.10,11 
However, the information appearing in these studies does not allow such 
a conclusion. In burn cases, as already seen through the present study, 
the use of albumin cannot be recommended. 
The multicenter Safe clinical trial published in 2004 compared the 
effect of using albumin with saline solution on the mortality rate among 
a heterogeneous population of 6997 patients hospitalized in intensive 
care units in 16 tertiary-level hospitals in Australia and New Zealand be-
tween November 2000 and June 2003.12 It showed that the use of albu-
min did not enable any change in the mortality rate, in comparison with 
the use of isotonic solutions to achieve the expected benefit in relation 
to mortality, thereby reaffirming the evidence from previous reviews. 
The present study, which involved a non-concurrent cohort, corrob-
orates and consolidates the evidence found by the Cochrane reviews in 
relation to burn patients, i.e. that the use of albumin is a risk factor for 
hospital mortality among such patients. Among the patients with mod-
erate and major burns who were treated with albumin, the risk of death 
was significantly higher in comparison with the risk run by patients who 
did not undergo this treatment.
Another possibility would be that only the patients with the severest 
burns should receive albumin. However, the observed increase in mor-
tality was greater among the less severely affected patients (moderate 
burns). In other clinical situations, the Cochrane studies objectively in-
dicated that the use of albumin did not produce any benefit for patients, 
in comparison with the use of crystalloids.6,7
Another important matter relates to the possible problems associ-
ated with administering albumin in clinical practice, which include the 
following: 
- Products derived from blood are not pure and there are large qual-
ity differences in albumin preparations. The presence of endotoxins, 
polymers, bradykinin and other proteins may alter the quality of the 
albumin and result in anaphylaxis.13
- A large proportion of critically ill patients present increased capil-
lary fragility and extravasation of albumin to interstitial areas, which 
may cause pulmonary edema. The pulmonary lymphatic system 
only has limited capacity for removing large volumes of fluids from 
interstitial areas, thereby giving rise to greater vulnerability towards 
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edema. There is evidence to suggest that pulmonary dysfunction 
among critically ill patients does not depend on the osmotic pres-
sure of the plasma. The deleterious effects of albumin on the lungs 
may be produced by various factors, including secondary hyperv-
olemia due to antinatriuresis and antidiuresis, and by changes in 
secondary oncotic pressure due to increased extravascular albumin 
in the lungs. Burn patients treated with colloids may have a high 
level of water retention in the lungs for up to seven days after receiv-
ing the injury.13
- There may be worsening of the inflammatory processes among pa-
tients treated with albumin, because this affects the hemodynamics 
of the microcirculation. Another effect, paradoxically, is a decrease 
in the glomerular filtration rate, through a mechanism that is still 
unknown.13 A likely explanation is that the albumin increases the 
oncotic pressure inside the peritubular vessels, thus causing a de-
crease in the excretion of sodium and water. Albumin, contrary to 
what is believed, does not boost the natriuresis of furosemide.13 It is 
more likely that it aggregates furosemide in the renal tubules, there-
by promoting its inactivation and diminishing its diuretic effect.13 
- Several other effects have been reported, such as the occurrence of 
urticaria, fever and shivers.13
With regard to the efficacy and effectiveness of the use of albumin, 
the literature available and the results from the present study have in-
dicated that there is no evidence to support continuing to use it indis-
criminately. If these arguments are not enough, comparison of the effi-
ciency of treatments using albumin and crystalloid solutions shows that 
the differences are significant. The price difference between one prod-
uct and the other is of the order of up to 100-fold. The amount paid by 
hospitals in Brazil for 20% albumin solution ranges from R$ 37.00 to 
R$ 155.00, while the SUS price tables reimburse R$ 55.00 for a 50-ml 
flask. The annual mean number of flasks paid for by SUS over the last 
seven years (2000 to 2006) was 247,230, with an annual mean expendi-
ture of R$ 13,597,650.00, for all clinical conditions. The total expendi-
ture on albumin in Brazil can be expected to greatly exceed this amount, 
if the expenditure by the supplementary health system and direct expen-
diture by society are taken into account, but unfortunately these data 
are not available. On the other hand, the market price for units of crys-
talloid solutions ranges from R$ 0.77 to R$ 2.55.
The results presented have indicated that, among burn patients, the 
use of albumin are deleterious, thus confirming the investigations car-
ried out by the Injuries Group Albumin Review.6,7 
There is still much controversy in relation to whether or not to use 
albumin in healthcare services. Nonetheless, most of the studies that 
have been published defend the need to carry out further research on 
this subject. 
CONCLUSIONS
The use of albumin for patients who are classified as presenting 
moderate and major burns is associated with a great increase in mortal-
ity. Therefore, until it is proven to the contrary, human albumin must 
not be used any more for burn patients at any level, and its use must be 
restricted to clinical research and physiopathological studies.
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